Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Aligos Therapeutics, Inc. - Common stock
(NQ:
ALGS
)
9.170
+0.410 (+4.68%)
Streaming Delayed Price
Updated: 11:10 AM EST, Jan 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aligos Therapeutics, Inc. - Common stock
< Previous
1
2
3
4
5
6
7
8
Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
↗
May 15, 2023
We're starting off the week with a breakdown of the biggest pre-market stock movers worth keeping an eye on Monday morning!
Via
InvestorPlace
Aligos Therapeutics Announces Research Collaboration and Development Agreement with Xiamen Amoytop Biotech Co. Ltd. for Use of Aligos’ Oligonucleotide Platform for the Treatment of Liver Diseases
May 12, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Recap: Aligos Therapeutics Q1 Earnings
↗
May 04, 2023
Via
Benzinga
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2023 Financial Results
May 04, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Earnings Preview
↗
May 03, 2023
Via
Benzinga
Aligos Therapeutics Earnings Perspective: Return On Capital Employed
↗
March 14, 2023
Via
Benzinga
Aligos Therapeutics to Announce First Quarter Results on May 4, 2023
April 27, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs at the European Association for the Study of the Liver (EASL) Congress 2023
April 11, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Presents Clinical Data from NASH Program at the 2023 Paris Hepatology Conference
March 29, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
A Preview Of Aligos Therapeutics's Earnings
↗
March 08, 2023
Via
Benzinga
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial Results
March 09, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Announce Fourth Quarter Results March 9, 2023
February 28, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Presents Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver
February 16, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Present Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver
February 14, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Present at the SVB Securities Global Biopharma Conference
February 10, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Reprioritizes Pipeline With Focus On NASH, COVID Programs, Cuts Another 10% Of Its Workforce
↗
February 09, 2023
Via
Benzinga
Aligos Therapeutics Announces Strategic Reprioritization of NASH and COVID-19 Programs and Confirms Key Timelines and Extension of Cash Runway to Year-End 2024
February 08, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Why Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
January 17, 2023
Gainers Celyad Oncology SA (NASDAQ: CYAD) jumped 187% to $2.30 after gaining 21% on Friday. Celyad Oncology, last month, decided to discontinue the development of its remaining clinical program...
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
↗
January 16, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
↗
January 06, 2023
Via
Benzinga
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session
↗
January 06, 2023
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process.
Via
Benzinga
Aligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009
January 05, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023
↗
January 06, 2023
Via
Benzinga
Aligos Therapeutics Initiates Dosing with its Small Interfering RNA (siRNA) Drug Candidate, ALG-125755, in Subjects with Chronic Hepatitis B (CHB)
December 14, 2022
Single and multiple ascending doses to be evaluated in CHB subjects throughout 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Presents Nonclinical Data for its Coronavirus Therapeutic Program at the 2022 Respi DART Meeting
December 08, 2022
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Presents Clinical Data for its NASH Program and Nonclinical Data for its Chronic Hepatitis B Portfolio at AASLD’s The Liver Meeting® 2022
November 04, 2022
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Presents Clinical Data for its Capsid Assembly Modulator, ALG-000184, at AASLD’s The Liver Meeting® 2022
November 04, 2022
Reductions in hepatitis B surface antigen levels observed in a subset of subjects with chronic hepatitis B enrolled in Phase 1 study ALG-000184-201
From
Aligos Therapeutics
Via
GlobeNewswire
SVB Leerink Maintains Market Perform Rating for Aligos Therapeutics: Here's What You Need To Know
↗
November 03, 2022
SVB Leerink has decided to maintain its Market Perform rating of Aligos Therapeutics (NASDAQ:ALGS) and lower its price target from $3.00 to $2.00. Shares of Aligos Therapeutics are trading up 0.0% over...
Via
Benzinga
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial Results
November 02, 2022
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLD’s The Liver Meeting® 2022
October 21, 2022
From
Aligos Therapeutics
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
